Overview

Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The main objective is to determine the safety and tolerability of combination decitabine and bexarotene during four cycles of therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Azacitidine
Bexarotene
Decitabine